{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:10:45Z","timestamp":1777421445346,"version":"3.51.4"},"reference-count":29,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T00:00:00Z","timestamp":1659052800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The main objective of this article is to review the immunogenicity and safety of the 3-antigen recombinant hepatitis B vaccine (3A-HepB) in adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>A literature search was performed using PubMed and Google Scholar (2000 to June 2022) with the search terms hepatitis B vaccine and 3-antigen. Other resources included the Centers for Disease Control and Prevention, conference abstracts of liver meetings, the prescribing information, and the manufacturer\u2019s website.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>All English-language articles of studies assessing the immunogenicity and safety of 3A-HepB in humans were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>The 3A-HepB is licensed to prevent infection caused by all known subtypes of the hepatitis B virus in adults. It contains 3 hepatitis B surface antigens. The 3A-HepB has been shown to be noninferior to a single-antigen hepatitis B vaccine (1A-HepB). It is administered intramuscularly as a 3-dose series at 0, 1, and 6 months. The most commonly reported local reactions were injection site pain and tenderness, and the most commonly reported systemic reactions were headache, fatigue, and myalgia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice:<\/jats:title>\n                    <jats:p>The introduction of 3A-HepB represents another step toward reducing the rates of new hepatitis B infections. However, clinical trials are needed to assess the immunogenicity of 3A-HepB in individuals at high-risk of nonresponse or low response to 1A-HepB, such as those with renal or hepatic impairment and those with altered immunocompetence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The 3A-HepB represents another vaccine to prevent hepatitis B in adults. It is safe and immunogenic but is associated with more adverse reactions than 1A-HepB.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280221114469","type":"journal-article","created":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T02:50:34Z","timestamp":1659149434000},"page":"325-332","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["PreHevbrio: A New 3-Antigen Hepatitis B Vaccine for Adults"],"prefix":"10.1177","volume":"57","author":[{"given":"Allana J.","family":"Sucher","sequence":"first","affiliation":[{"name":"Regis University School of Pharmacy, Denver, CO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandon J.","family":"Sucher","sequence":"additional","affiliation":[{"name":"Regis University School of Pharmacy, Denver, CO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1775-9497","authenticated-orcid":false,"given":"Elias B.","family":"Chahine","sequence":"additional","affiliation":[{"name":"Palm Beach Atlantic University, Gregory School of Pharmacy, West Palm Beach, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,7,29]]},"reference":[{"key":"bibr1-10600280221114469","volume-title":"Epidemiology and Prevention of Vaccine-Preventable Diseases","author":"Centers for Disease Control and Prevention","year":"2021","edition":"14"},{"key":"bibr2-10600280221114469","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8030456."},{"key":"bibr3-10600280221114469","unstructured":"Centers for Disease Control and Prevention.Viral hepatitis: hepatitis B information\u2014questions and answers for health professionals. Accessed June 15, 2022. https:\/\/www.cdc.gov\/hepatitis\/hbv\/hbvfaq.htm"},{"key":"bibr4-10600280221114469","unstructured":"Centers for Disease Control and Prevention. Viral hepatitis surveillance report\u2014United States, 2019. Published May 2021. Accessed June 15, 2022. https:\/\/www.cdc.gov\/hepatitis\/statistics\/2019surveillance\/index.htm"},{"key":"bibr5-10600280221114469","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7113a1"},{"key":"bibr6-10600280221114469","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000651"},{"key":"bibr7-10600280221114469","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31782"},{"key":"bibr8-10600280221114469","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7107a1"},{"key":"bibr9-10600280221114469","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr6701a1."},{"key":"bibr10-10600280221114469","unstructured":"Engerix-B [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; 2021."},{"key":"bibr11-10600280221114469","unstructured":"Recombivax HB [prescribing information]. Whitehouse Station, NJ: Merck and Co; 2020."},{"key":"bibr12-10600280221114469","unstructured":"Heplisav-B [prescribing information]. Emeryville, CA: Dynavax Technologies Corporation; 2020."},{"key":"bibr13-10600280221114469","unstructured":"PreHevbrio [prescribing information]. Cambridge, MA: VBI Vaccines; 2021."},{"key":"bibr14-10600280221114469","unstructured":"Twinrix [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; 2018."},{"key":"bibr15-10600280221114469","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01035."},{"key":"bibr16-10600280221114469","unstructured":"U.S. Food & Drug Administration.Vaccines, blood, and biologics: PreHevbrio. Accessed June 15, 2022. https:\/\/www.fda.gov\/vaccines-blood-biologics\/prehevbrio"},{"key":"bibr17-10600280221114469","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-8278(03)00152-1."},{"key":"bibr18-10600280221114469","doi-asserted-by":"publisher","DOI":"10.1007\/s00430-014-0374-x."},{"issue":"5","key":"bibr19-10600280221114469","first-page":"328","volume":"3","author":"Raz R","year":"2001","journal-title":"Isr Med Assoc J"},{"key":"bibr20-10600280221114469","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.01.007."},{"key":"bibr21-10600280221114469","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30780-5."},{"key":"bibr22-10600280221114469","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.28652."},{"key":"bibr23-10600280221114469","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.05.067."},{"key":"bibr24-10600280221114469","unstructured":"The European Association for the Study of Liver. International Liver Congress 2022 Abstract Book. Accessed June 16, 2022. https:\/\/easl.eu\/wp-content\/uploads\/2022\/06\/ILC-2022-Abstract-Book-15.06-Web.pdf"},{"key":"bibr25-10600280221114469","doi-asserted-by":"publisher","DOI":"10.1159\/000078403."},{"issue":"3","key":"bibr26-10600280221114469","first-page":"143","volume":"19","author":"Alon D","year":"2017","journal-title":"Isr Med Assoc J"},{"key":"bibr27-10600280221114469","unstructured":"Red Book Online [database online]. Greenwood Village, CO: Truven Health Analytics. Accessed June 15, 2022. http:\/\/www.micromedexsolutions.com\/"},{"key":"bibr28-10600280221114469","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2022.04.736"},{"key":"bibr29-10600280221114469","unstructured":"VBI Vaccines.Press Releases: VBI vaccines announces PreHevbrio\u2122 [hepatitis B vaccine (recombinant)] recommended by CDC Advisory Committee on Immunization Practices for the prevention of hepatitis B in adults. Accessed June 15, 2022. https:\/\/www.vbivaccines.com\/hepatitis-b\/prehevbrio-recommended-cdc-acip-for-the-prevention-of-hepatitis-b\/"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280221114469","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280221114469","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280221114469","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:17:00Z","timestamp":1777375020000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280221114469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,29]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1177\/10600280221114469"],"URL":"https:\/\/doi.org\/10.1177\/10600280221114469","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,29]]}}}